Cogent Biosciences (COGT) Receivables (2017 - 2019)

Cogent Biosciences (COGT) has reported Receivables for 3 consecutive years, with $2.0 million the latest figure, recorded in Q4 2019.

• In Q4 2019, Receivables rose 19.9% year-over-year to $2.0 million; the TTM figure through Dec 2019 stood at $2.0 million (up 19.9% YoY), while the FY2019 annual figure was $2.0 million, up 19.9% from the prior year.
• Receivables rose to $2.0 million in Q4 2019 per COGT's latest filing, from $880000.0 in the prior quarter.
• Across five years, Receivables topped out at $2.0 million in Q1 2019 and bottomed at $830000.0 in Q4 2017.
• Historically, Receivables has averaged $1.5 million across 3 years, with a median of $1.5 million in 2019.
• Annual changes were most pronounced in 2018 — Receivables soared 100.96% — and 2019, when it slumped 37.98%.
• Cogent Biosciences' Receivables stood at $830000.0 in 2017, then jumped by 100.96% to $1.7 million in 2018, then rose by 19.9% to $2.0 million in 2019.
• Business Quant data shows COGT's Receivables at $2.0 million in Q4 2019, $880000.0 in Q3 2019, and $1.5 million in Q2 2019.